PMLiVE20h
EC approves CSL’s Andembry to prevent hereditary angioedema attacks
The European Commission (EC) has approved CSL’s Andembry (garadacimab) to prevent attacks of hereditary angioedema (HAE) in ...
PMLiVE20h
Roche’s Evrysdi tablet formulation granted FDA approval for spinal muscular atrophy
Roche has announced that a tablet formulation of its spinal muscular atrophy (SMA) treatment Evrysdi (risdiplam) has been ...
PMLiVE20h
AbbVie and Xilio announce immunotherapy partnership worth over $2.1bn
AbbVie and Xilio Therapeutics have announced a partnership worth over $2.1bn to develop tumour-activated, antibody-based immunotherapies. The collaboration and option-to-licence agreement will include ...
PMLiVE1d
Pfizer granted FDA approval for Adcetris combination in large B-cell lymphoma
Pfizer’s Takeda-partnered blood cancer drug Adcetris (brentuximab vedotin) has been approved by the US Food and Drug ...
PMLiVE1d
Eli Lilly and OliX partner to advance early-stage metabolic disease candidate
Eli Lilly and RNAi therapeutics specialist OliX Pharmaceuticals have entered into a global licensing agreement to advance a ...
PMLiVE2d
Boehringer’s nerandomilast shows promise in phase 3 pulmonary fibrosis study
Boehringer Ingelheim (BI) has announced positive top-line results from a late-stage study of its investigational ...
PMLiVE3d
Eli Lilly shares two-year results for Omvoh in active Crohn’s disease patients
Eli Lilly has shared positive two-year results from an open-label extension (OLE) study of Omvoh (mirikizumab-mrkz) in active ...
PMLiVE2d
Novartis to expand cardiovascular pipeline with $3.1bn Anthos acquisition
Novartis has announced that it will be expanding its late-stage cardiovascular pipeline by acquiring Anthos Therapeutics for ...
PMLiVE2d
CSL Behring announces four-year results for haemophilia B gene therapy Hemgenix
CSL Behring has shared positive four-year results from a late-stage study of its haemophilia B gene therapy Hemgenix ...
PMLiVE3d
AbbVie announces FDA approval of antibiotic combination for intra-abdominal infections
AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo ...
PMLiVE8d
Shaping the future of pharma with human-centric transformation techniques
Ultimately, transformation isn’t about technology or processes – it’s about people. The organisations investing in their ...
PMLiVE1d
FDA approves SpringWorks Therapeutics’ Gomekli to treat neurofibromatosis type 1
The US Food and Drug Administration (FDA) has approved SpringWorks Therapeutics’ Gomekli (mirdametinib) to treat neurofibromatosis type 1 (NF1), a rare genetic disorder affecting approximately 100,000 ...